NCT01165203 - Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

July 6, 2012

Study Completion Date

May 14, 2013

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

Herpes Zoster Vaccine GSK1437173A

intramuscular injection

BIOLOGICAL

Placebo

intramuscular injection

Trial Locations (15)

13353

GSK Investigational Site, Berlin

20146

GSK Investigational Site, Hamburg

30625

GSK Investigational Site, Hanover

32803

GSK Investigational Site, Orlando

40237

GSK Investigational Site, Düsseldorf

44791

GSK Investigational Site, Bochum

45122

GSK Investigational Site, Essen

75246

GSK Investigational Site, Dallas

87505

GSK Investigational Site, Santa Fe

90813

GSK Investigational Site, Long Beach

94115

GSK Investigational Site, San Francisco

SE18 4QH

GSK Investigational Site, Woolwich, London

E1 1BB

GSK Investigational Site, London

NW3 2QG

GSK Investigational Site, London

SW10 9TH

GSK Investigational Site, London